Nordic Life Science 1
Nicklas Westerholm, CEO, PledPharma BUSINE S S D
E A L ”THE ACQUISITION OF RTT is an important step, building a new company with a strategic focus on the attractive orphan drug segment, with Aladote and Emcitate as the company’s key assets in late stage development. The RTT team, specialized in orphan drugs, will complement PledPharma’s late stage development focused organization, building a new orphan drug company named Egetis Therapeutics, dedicated to the development and commercialization of therapies for rare diseases,” says Nicklas Westerholm, CEO, PledPharma. “I look forward to working with the dedicated and competent RTT team with their proven track record from the orphan drug segment, including companies such as Sobi, Wilson Therapeutics and Medical Need Europe.” PHOTO MARTIN BOTVIDSSON